Coronavirus Update: End Of The Road For Kevzara In COVID-19

Plus: J&J Start Phase I Vaccine Trial In Japan

Sanofi/Regeneron are ending development of Kevzara for COVID-19 after Phase III disappointments. Meanwhile Regeneron is ramping up biologics manufacturing in Ireland as it makes way for COVID-19 antibody production in New York, and multiple vaccines move forward in Japan with new funding and trials.

Inscription COVID-19 on blue background. World Health Organization WHO introduced new official name for Coronavirus disease named COVID-19
• Source: Shutterstock

Sanofi/Regeneron Pharmaceuticals, Inc.'s interleukin-6 inhibitor Kevzara (sarilumab) will not be developed further for treatment of hospitalized COVID-19 patients after a Phase III trial in severely and critically ill patients failed to meet either its primary endpoint or key secondary endpoint.

The disappointing news isn't a surprise at this point, coming after Kevzara previously didn’t show a benefit in patients requiring...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip